Global Prostate Cancer Antigen 3 Test Market Growth (Status and Outlook) 2025-2031

The global Prostate Cancer Antigen 3 Test market size is predicted to grow from US$ 54.4 million in 2025 to US$ 93.3 million in 2031; it is expected to grow at a CAGR of 9.4% from 2025 to 2031.

The prostate cancer antigen 3 gene (PCA3) test is used to assess your risk of developing prostate cancer. It is not used to make a diagnosis of prostate cancer. It is primarily used to determine whether your elevated prostate-specific antigen (PSA) levels are the result of prostate cancer. Prostate cancer is a type of cancer that develops in the prostate gland of men and is increasing at a significant rate each year. This cancer is commonly found in the elderly population, and it can have serious consequences such as blood in the sperm, bone pain, and erectile dysfunction, among others. As a result, early detection is required to avoid it at an early stage.

The Global key players of Prostate Cancer Antigen 3 Test include Hologic, Thermo Fisher Scientific, MDxHealth, etc. The top three players hold a share about 77%. US & Canada is the largest market, and has a share about 37%. In terms of product type, RT-PCR is the largest segment, which occupied for a share of about 87%. For application, Hospital is the largest segment, which has a share about 61%.

LPI (LP Information)' newest research report, the “Prostate Cancer Antigen 3 Test Industry Forecast” looks at past sales and reviews total world Prostate Cancer Antigen 3 Test sales in 2024, providing a comprehensive analysis by region and market sector of projected Prostate Cancer Antigen 3 Test sales for 2025 through 2031. With Prostate Cancer Antigen 3 Test sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Prostate Cancer Antigen 3 Test industry.

This Insight Report provides a comprehensive analysis of the global Prostate Cancer Antigen 3 Test landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Prostate Cancer Antigen 3 Test portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Prostate Cancer Antigen 3 Test market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Prostate Cancer Antigen 3 Test and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Prostate Cancer Antigen 3 Test.

This report presents a comprehensive overview, market shares, and growth opportunities of Prostate Cancer Antigen 3 Test market by product type, application, key players and key regions and countries.

Segmentation by Type:

RT-PCR

ELISA Test

Segmentation by Application:

Hospital

Diagnosis Center

Other

This report also splits the market by region:

Americas

United States

Canada

Mexico

Brazil

APAC

China

Japan

Korea

Southeast Asia

India

Australia

Europe

Germany

France

UK

Italy

Russia

Middle East & Africa

Egypt

South Africa

Israel

Turkey

GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.

Hologic

Thermo Fisher Scientific

MDxHealth

Exosome Diagnostics GmbH

Copyright Creative Diagnostics

Lytech

YUBO

MicroDiag Biomedicine

Please note: The report will take approximately 2 business days to prepare and deliver.